Beryl Drugs Ltd. (BSE: 524606) is a Indore, Madhya Pradesh-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹12 Cr, it ranks #4,946 by market cap among the 6,137 Indian listed companies on FinBizNet, and #25 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹24.69 (as of 25 Oct 2026), the share price is 11.5% below its 52-week high of ₹27.90 and 55.1% above its 52-week low of ₹15.92. The share price is up 9.3% over one year and up 16.0% over three months.
| Current Price | ₹24.69 |
|---|---|
| Market Cap | ₹12 Cr |
| BSE Code | 524606 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 29.7 |
| Return on Equity | 4.38% |
| Return on Assets | 3.69% |
| 52-Week Range | ₹15.92 – ₹27.90 |
| 1-Year Price Change | +9.3% |
| 3-Month Price Change | +16.0% |
| Beta (1Y) | 0.42 |
| Headquarters | Indore, Madhya Pradesh |
| Website | www.beryldrugs.com |
Beryl Drugs Limited manufactures and markets pharmaceutical products in India. The company offers various branded and generic pharmaceutical formulations, bulk drugs, I.V. fluids, small volume injectables in liquid and dry powder forms, and eye and ear drops, as well as veterinary products. It also provides research and development, and contract manufacturing services. The company exports its products. Beryl Drugs Limited was incorporated in 1993 and is based in Indore, India.
1. Pharmaceutical Industry-This segment manufactures and markets generic pharmaceutical formulations in India. 2. Trading Division-This segment engages in the sale and export of branded, generic pharmaceutical formulations in India. 3. Manufacturing Division-This segment engages in the manufacture, sale, and export of branded, generic pharmaceutical formulations in India.
1. Pharmaceutical Industry-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,73,448 Cr | 71.2 | 16.98% | ₹4,979 Cr | +28.0% |
| Aether Industries Limited | ₹20,419 Cr | 92.1 | 9.81% | ₹327 Cr | +88.8% |
| Alivus Life Sciences Ltd | ₹16,073 Cr | 27.7 | 18.36% | ₹640 Cr | +33.8% |
| Aarti Pharmalabs Ltd | ₹7,922 Cr | 43.2 | 8.49% | ₹536 Cr | -4.1% |
| Solara Active Pharma Sciences Limited | ₹3,361 Cr | -382.6 | -0.63% | ₹417 Cr | +3.3% |
| Sai Parenteral's Limited | ₹2,153 Cr | 110.9 | 2.88% | ₹179 Cr | — |
| KRM Ayurveda Limited | ₹556 Cr | 25.9 | — | ₹32 Cr | — |
| Trident Lifeline Limited | ₹501 Cr | 24.8 | — | — | +39.4% |
| Beryl Drugs Ltd. | ₹12 Cr | 29.7 | 4.38% | — | +9.3% |
Listed by market capitalisation. Ratios are shown for context only.
Beryl Drugs Ltd. is trading at ₹24.69, with a market capitalisation of ₹12 Cr.
Beryl Drugs Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Beryl Drugs Ltd. has a P/E of 29.7 and a return on equity of 4.38%.
Beryl Drugs Ltd. is listed on the BSE under the scrip code 524606.
Beryl Drugs Ltd.'s share price is up 9.3% over one year and up 16.0% over three months. Its 52-week range is ₹15.92 to ₹27.90.
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.